Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
- Conditions
- First Posted Date
- 2005-02-21
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1455
- Registration Number
- NCT00104013
- Locations
- 🇺🇸
Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Synergy Medical, Saginaw, Michigan, United States
🇺🇸CNS Healthcare, Jacksonville, Florida, United States
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
- Conditions
- First Posted Date
- 2005-02-14
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1306
- Registration Number
- NCT00103649
- Locations
- 🇺🇸
Neurology Clinical Research, Inc., Plantation, Florida, United States
🇺🇸Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
- First Posted Date
- 2004-10-29
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 43
- Registration Number
- NCT00094965
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-10-14
- Last Posted Date
- 2010-02-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 861
- Registration Number
- NCT00094081
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸H-Lee Moffitt Cancer Center and Research, Tampa, Florida, United States
HP184 in Chronic Spinal Cord Injury Subjects
- Conditions
- First Posted Date
- 2004-10-07
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 262
- Registration Number
- NCT00093275
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺sanofi-aventis administrative Australia & New-Zealand administrative office, Macquarie Park, New South Wales, Australia
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
- Conditions
- First Posted Date
- 2004-07-20
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 168
- Registration Number
- NCT00087958
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2009-04-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 383
- Registration Number
- NCT00087802
- Locations
- 🇺🇸
Dayton Oncology & Hematology, P.A., Kettering, Ohio, United States
🇺🇸Interlakes Oncology & Hematology, P.C., Rochester, New York, United States
🇺🇸Florida Cancer Institute, New Port Richey, Florida, United States
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 438
- Registration Number
- NCT00081796
- Locations
- 🇨🇱
Las Condes, Santiago, Chile
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
- Conditions
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3532
- Registration Number
- NCT00077844
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20506
- Registration Number
- NCT00077792
- Locations
- 🇦🇷
sanofi-aventis administrative Office, Buenos Aires, Argentina
🇫🇷Sanofi- Aventis Administrative Office, Paris, France
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia